LeMaitre Vascular Reports Strong Q1 2026 Earnings Growth and Strategic Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy LMAT?
Source: seekingalpha
- Significant Sales Growth: LeMaitre Vascular achieved an 11% sales increase in Q1 2026, with a gross margin of 72.7% and a 42% rise in EPS, indicating strong market performance and enhanced profitability.
- Outstanding Artegraft Performance: Artegraft has become the company's largest product, with worldwide sales growing 36% and international sales reaching $2.1 million, while 2026 sales are projected to hit $10 million, reflecting robust demand in international markets.
- Improved Profitability: Q1 operating income rose 41% year-over-year to $17.8 million, with an operating margin increasing from 21% in 2025 to 27%, demonstrating significant progress in cost control and efficiency improvements.
- Optimistic Future Outlook: The company affirmed its full-year revenue guidance of $280 million, expecting 12% organic growth, while raising EPS expectations to $3, showcasing management's confidence in future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LMAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LMAT
Wall Street analysts forecast LMAT stock price to fall
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 111.530
Low
93.00
Averages
105.20
High
120.00
Current: 111.530
Low
93.00
Averages
105.20
High
120.00
About LMAT
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which are used in open vascular surgery and dialysis access. It offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold globally in the United States, Europe, Canada and Asia Pacific.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LeMaitre Vascular Reports Strong Q1 2026 Earnings Growth and Strategic Outlook
- Significant Sales Growth: LeMaitre Vascular achieved an 11% sales increase in Q1 2026, with a gross margin of 72.7% and a 42% rise in EPS, indicating strong market performance and enhanced profitability.
- Outstanding Artegraft Performance: Artegraft has become the company's largest product, with worldwide sales growing 36% and international sales reaching $2.1 million, while 2026 sales are projected to hit $10 million, reflecting robust demand in international markets.
- Improved Profitability: Q1 operating income rose 41% year-over-year to $17.8 million, with an operating margin increasing from 21% in 2025 to 27%, demonstrating significant progress in cost control and efficiency improvements.
- Optimistic Future Outlook: The company affirmed its full-year revenue guidance of $280 million, expecting 12% organic growth, while raising EPS expectations to $3, showcasing management's confidence in future performance.
See More
LeMaitre Vascular Earnings Preview
- Revenue Beat: LeMaitre Vascular reported $64.45 million in revenue last quarter, a 15.7% year-over-year increase that not only surpassed analyst expectations but also provided strong support for next quarter's EPS guidance, indicating robust growth in the medical device sector.
- Optimistic Market Expectations: This quarter, the market anticipates an 11.4% year-over-year revenue growth for LeMaitre, aligning with the 12% increase recorded in the same quarter last year, reflecting analysts' optimistic outlook despite the company's history of missing Wall Street revenue estimates.
- Peer Performance Insights: In the healthcare equipment and supplies sector, Intuitive Surgical and Baxter reported revenue growth of 23% and 2.9%, respectively, exceeding analyst expectations, which may positively influence LeMaitre's performance by reflecting overall industry trends.
- Stable Stock Price: While the healthcare equipment sector saw an average stock price increase of 6% over the past month, LeMaitre's stock price remained unchanged at $108.97, with an average analyst price target of $111.22, indicating cautious optimism regarding its future growth potential.
See More
LeMaitre Vascular to Present at Needham Healthcare Conference
- Conference Presentation: LeMaitre Vascular will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2025, at 2:15 PM EDT, showcasing its latest advancements in treating peripheral vascular disease.
- Company Overview: LeMaitre Vascular focuses on providing devices, implants, and services for peripheral vascular disease, a condition affecting over 200 million people globally, highlighting its market potential and social responsibility.
- Product Development: The company develops, manufactures, and markets disposable and implantable vascular devices to meet the needs of its core customers, vascular surgeons, thereby driving business growth and increasing market share.
- Information Access: Additional information can be found on the company’s website www.lemaitre.com, demonstrating its commitment to transparency and effective communication with customers.
See More
LeMaitre Vascular Executive Sells Shares Amid Strong Growth
- Transaction Overview: On March 11, 2026, Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised and sold 2,625 shares of common stock for approximately $285,000, at a weighted average price of $108.50 per share, reflecting the company's strong stock performance.
- Ownership Change: This transaction reduced Kamke's direct holdings to 6,677 shares, representing 28.22% of his previous stake, indicating a significant shift in his equity position that could influence future decision-making and incentive structures.
- Financial Performance Highlights: LeMaitre reported a 16% year-over-year sales increase to $64.5 million in Q4 2025, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's robust growth potential in the medical device sector.
- Future Outlook: The company expects a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's competitive strength and ongoing profitability, although analysts remain cautious about its future performance.
See More
LeMaitre Vascular Executive Stock Transaction Analysis
- Executive Stock Transaction: On March 11, 2026, LeMaitre Vascular's Senior Vice President Trent G Kamke sold 2,625 shares of common stock for approximately $285,000, reflecting a common practice among executives to monetize equity awards while adhering to company trading policies.
- Ownership Changes: Kamke's direct holdings decreased from about 9,000 shares to 6,677 shares, marking a 28.22% reduction in direct equity exposure, yet he retains 1,353 stock options that can be exercised for additional shares, preserving potential upside alignment with company performance.
- Company Financial Performance: In Q4 2025, LeMaitre reported a 16% year-over-year sales increase to $64.5 million, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's strong growth in the medical device sector.
- Future Outlook: The company anticipates a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's ongoing growth potential in the medical device market, which enhances investor confidence in its future performance.
See More
LeMaitre Vascular Executive Stock Transaction Overview
- Executive Stock Transaction: Trent G. Kamke, Senior VP of Operations at LeMaitre Vascular, exercised and immediately sold 2,625 shares of common stock on March 11, 2026, for approximately $285,000, indicating executive focus on liquidity.
- Ownership Change: Following the transaction, Kamke's direct holdings decreased to 6,677 shares, reflecting that this sale represented 28.22% of his pre-sale direct holdings, aligning with his recent trading patterns and demonstrating confidence in the market.
- Company Financial Performance: LeMaitre Vascular reported a 16% increase in fourth-quarter sales to $64.5 million and a 47% surge in operating income to $18.8 million, showcasing strong pricing power and manufacturing efficiencies that boosted overall performance.
- Future Outlook: The company projects approximately $280 million in full-year sales for 2026, raised its dividend by 25%, and initiated a $100 million buyback program, indicating strong confidence in future growth and commitment to shareholder returns.
See More
LeMaitre Vascular Reports Strong Q1 2026 Earnings Growth and Strategic Outlook
- Significant Sales Growth: LeMaitre Vascular achieved an 11% sales increase in Q1 2026, with a gross margin of 72.7% and a 42% rise in EPS, indicating strong market performance and enhanced profitability.
- Outstanding Artegraft Performance: Artegraft has become the company's largest product, with worldwide sales growing 36% and international sales reaching $2.1 million, while 2026 sales are projected to hit $10 million, reflecting robust demand in international markets.
- Improved Profitability: Q1 operating income rose 41% year-over-year to $17.8 million, with an operating margin increasing from 21% in 2025 to 27%, demonstrating significant progress in cost control and efficiency improvements.
- Optimistic Future Outlook: The company affirmed its full-year revenue guidance of $280 million, expecting 12% organic growth, while raising EPS expectations to $3, showcasing management's confidence in future performance.
See More
LeMaitre Vascular Earnings Preview
- Revenue Beat: LeMaitre Vascular reported $64.45 million in revenue last quarter, a 15.7% year-over-year increase that not only surpassed analyst expectations but also provided strong support for next quarter's EPS guidance, indicating robust growth in the medical device sector.
- Optimistic Market Expectations: This quarter, the market anticipates an 11.4% year-over-year revenue growth for LeMaitre, aligning with the 12% increase recorded in the same quarter last year, reflecting analysts' optimistic outlook despite the company's history of missing Wall Street revenue estimates.
- Peer Performance Insights: In the healthcare equipment and supplies sector, Intuitive Surgical and Baxter reported revenue growth of 23% and 2.9%, respectively, exceeding analyst expectations, which may positively influence LeMaitre's performance by reflecting overall industry trends.
- Stable Stock Price: While the healthcare equipment sector saw an average stock price increase of 6% over the past month, LeMaitre's stock price remained unchanged at $108.97, with an average analyst price target of $111.22, indicating cautious optimism regarding its future growth potential.
See More
LeMaitre Vascular to Present at Needham Healthcare Conference
- Conference Presentation: LeMaitre Vascular will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2025, at 2:15 PM EDT, showcasing its latest advancements in treating peripheral vascular disease.
- Company Overview: LeMaitre Vascular focuses on providing devices, implants, and services for peripheral vascular disease, a condition affecting over 200 million people globally, highlighting its market potential and social responsibility.
- Product Development: The company develops, manufactures, and markets disposable and implantable vascular devices to meet the needs of its core customers, vascular surgeons, thereby driving business growth and increasing market share.
- Information Access: Additional information can be found on the company’s website www.lemaitre.com, demonstrating its commitment to transparency and effective communication with customers.
See More
LeMaitre Vascular Executive Sells Shares Amid Strong Growth
- Transaction Overview: On March 11, 2026, Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised and sold 2,625 shares of common stock for approximately $285,000, at a weighted average price of $108.50 per share, reflecting the company's strong stock performance.
- Ownership Change: This transaction reduced Kamke's direct holdings to 6,677 shares, representing 28.22% of his previous stake, indicating a significant shift in his equity position that could influence future decision-making and incentive structures.
- Financial Performance Highlights: LeMaitre reported a 16% year-over-year sales increase to $64.5 million in Q4 2025, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's robust growth potential in the medical device sector.
- Future Outlook: The company expects a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's competitive strength and ongoing profitability, although analysts remain cautious about its future performance.
See More
LeMaitre Vascular Executive Stock Transaction Analysis
- Executive Stock Transaction: On March 11, 2026, LeMaitre Vascular's Senior Vice President Trent G Kamke sold 2,625 shares of common stock for approximately $285,000, reflecting a common practice among executives to monetize equity awards while adhering to company trading policies.
- Ownership Changes: Kamke's direct holdings decreased from about 9,000 shares to 6,677 shares, marking a 28.22% reduction in direct equity exposure, yet he retains 1,353 stock options that can be exercised for additional shares, preserving potential upside alignment with company performance.
- Company Financial Performance: In Q4 2025, LeMaitre reported a 16% year-over-year sales increase to $64.5 million, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's strong growth in the medical device sector.
- Future Outlook: The company anticipates a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's ongoing growth potential in the medical device market, which enhances investor confidence in its future performance.
See More
LeMaitre Vascular Executive Stock Transaction Overview
- Executive Stock Transaction: Trent G. Kamke, Senior VP of Operations at LeMaitre Vascular, exercised and immediately sold 2,625 shares of common stock on March 11, 2026, for approximately $285,000, indicating executive focus on liquidity.
- Ownership Change: Following the transaction, Kamke's direct holdings decreased to 6,677 shares, reflecting that this sale represented 28.22% of his pre-sale direct holdings, aligning with his recent trading patterns and demonstrating confidence in the market.
- Company Financial Performance: LeMaitre Vascular reported a 16% increase in fourth-quarter sales to $64.5 million and a 47% surge in operating income to $18.8 million, showcasing strong pricing power and manufacturing efficiencies that boosted overall performance.
- Future Outlook: The company projects approximately $280 million in full-year sales for 2026, raised its dividend by 25%, and initiated a $100 million buyback program, indicating strong confidence in future growth and commitment to shareholder returns.
See More
